Founder and CEO at Eneas International, a private equity firm based in Madrid that invests in disruptive tech-enabled companies in Spain and Portugal.
Founder and CEO at Eneas International, a private equity firm based in Madrid that invests in disruptive tech-enabled companies in Spain and Portugal. I also serve as CEO of Lug Healthcare Technology, one of our innovative portfolio companies, whose software platform is revolutionizing the way that hospitals worldwide prepare and deliver medications to patients.
When I am not investing in emerging companies and helping them expand into Latin America and other markets, my focus is on building communities in my adopted hometown of Boston. I am passionate about social entrepreneurship, impact investing and conscious capitalism.
Currently, it is recognized and accepted by the most prestigious American and European organizations that lung cancer in its early stages must be operated by minimally invasive, that is, by holes no greater than 25mm in which no instrument is used that separates ribs, with this method a correct and complete oncological surgery can be obtained, which also offers many benefits to the patient, such as: less pain, faster recovery, fewer days of hospitalization, better oncological response, reduction in hospital costs.
It is defined as an excessive production of sweat in one or more regions of the body, generally due to an excess secretion of sweat dependent on the innervation of the sympathetic nervous system. The anatomical regions that are most frequently affected are the face, armpits and palms.